Patients with primary acute myeloid leukaemia were treated with induction therapy consisting of daunorubicin 50 mg/m2 (days 1 and 2) and continuous cytosine arabinoside 400 mg/m2 (days 15) with a 710-day gap between courses. Consolidation therapy consisted of one further similar course and a ...
The Food and Drug Administration (FDA), USA, on September 1, 2020, for the continued treatment of AML in patients in remission. The European Medicines Agency (EMA), in May 2020 as an injectable medicine under the name Vidaza for: - Myelodysplastic syndromes. - Chronic myelomonocytic leukaemia...
How good are we at predicting the fate of someone with acute myeloid leukaemia? Leukemia. 2017;31:1255–8. Article CAS Google Scholar Livingston E. Success of antibiotic therapy vs laparoscopic appendectomy for uncomplicated appendicitis in children; a matter of perspective. JAMA. 2020;324:594. ...
As the only treatment with curative intent is intensive chemotherapy, this presents an immediate therapeutic challenge for the majority of the disease.关键词: Acute Myeloid Leukaemia in Children Cytosine Arabinoside Anthracycline‐Immunotherapy DOI: 10.7861/clinmedicine.13-6-s58 被引量: 9 ...
have revolutionized Acute Myeloid Leukaemia treatment, shifting from standardized chemotherapy to personalized approaches. FDA-approved targeted drugs such as FLT3, IDH1, and IDH2 inhibitors, along with mutation-independent agents like venetoclax, highlight the precision in Acute Myeloid Leukaemia manageme...
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: Results of treatment with 5 multiple-drug schedules Br J Haematol, 27 (1974), p. 373 Google Scholar 21 JP Lewis, JW Linman, J Marshall, TF Pajak, JR Bateman...
The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising therapies entering clinical translation, yet patient responses remain heterogeneous, and biomarkers for tailoring treatment are lacking. To understand how disease heterog
The development of new treatments for older patients with acute myeloid leukaemia (AML) is an active area, but has met with limited success. Sapacitabine i... A,K,Burnett,... - 《Leukemia》 被引量: 25发表: 2015年 Oral idarubicin and low dose cytarabine as the initial treatment of acut...
Cancer immunotherapy has revolutionized the treatment of a growing number of human cancers. Although therapeutic cancer vaccines have not been successful in subjects with large tumor burden, they may be useful as consolidation therapy for AML in the MRD state [9,10]. The underlying strategy of can...
Current status and research directions in acute myeloid leukemia Article Open access 19 September 2024 Two decades of targeted therapies in acute myeloid leukemia Article 15 February 2021 FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm Article Open access 27 May 2021 Introduction...